Biotech Values

[WorstLuck]

MTSR (PFE VKTX)

Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-closes-73-billion-takeover-anti-obesity-drugmaker-metsera-ft-reports-2025-09-22/

Pfizer to pay $47.50/share for Metsera, plus up to $22.50 tied to milestones - FT
Deal may be announced Monday, pending final talks - FT
Pfizer eyes anti-obesity market after setbacks
Sept 21 (Reuters) - Pfizer (PFE.N), opens new tab is closing in on a potential $7.3 billion takeover of weight-loss drug developer Metsera (MTSR.O), opens new tab, the Financial Times reported on Sunday, citing unidentified sources.
The U.S. pharma firm will acquire New York City-based Metsera for $47.50 per share in cash, with an additional $22.50 per share contingent on the achievement of certain performance milestones, the newspaper said, adding that the announcement could come as early as Monday, unless deal talks fall through.
Reuters could not immediately confirm the report. Pfizer and Metsera did not immediately respond to a Reuters request for comment outside regular business hours.
Talks to acquire Metsera come just months after the biotech firm's blockbuster Nasdaq debut, underscoring surging investor appetite for companies developing next-generation weight-loss therapies.
The $47.50-per-share bid marks a roughly 42.5% premium over Metsera's Friday closing price of $33.32, which pegged its market value at about $3.5 billion, according to LSEG data.
The deal marks Pfizer's latest bid to secure a foothold in the lucrative anti-obesity drug market, following setbacks in its own development efforts.